Literature DB >> 20082533

Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells.

Mei Mei1, Yu Ren, Xuan Zhou, Xu-bo Yuan, Lei Han, Guang-xiu Wang, Zhifan Jia, Pei-yu Pu, Chun-sheng Kang, Zhi Yao.   

Abstract

The successful of anti-cancer treatment are often limited by the development of drug resistance. Recent work has highlighted the involvement of non-coding RNAs, microRNAs(miRNAs) in cancer development, and their possible involvement in the evolution of drug resistance has been proposed. In this study, we combine taxol chemotherapy and miR-21 inhibitor treatment via polyamidoamine (PAMAM) dendrimers vector to evaluate the effects of combination therapy on suppression of breast cancer cells. The 50% inhibitory concentration (IC50) values for taxol were significantly decreased to a greater extent in the cells transfected with miR-21 inhibitor compared with cells treated with taxol alone. Taxol treatment also increased the percentage of apoptotic breast cancer cells in miR-21 inhibitor transfected cells compared with control cells. Furthermore, treatment of the miR-21 inhibitor-transfected cells with the anti-cancer drugs taxol resulted in significantly reduced cell viability and invasiveness compared with control cells. These results indicated that the miR-21 plays an important role in the resistance of breast carcinoma cells to chemotherapeutic drugs. Therefore, miR-21 inhibitor gene therapy combined with taxol chemotherapy might represent a promising novel therapeutic approach for the treatment of breast malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20082533     DOI: 10.1177/153303461000900109

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  42 in total

Review 1.  The therapeutic potential of microRNAs: disease modulators and drug targets.

Authors:  Ailbhe M McDermott; Helen M Heneghan; Nicola Miller; Michael J Kerin
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

2.  Human anti-nucleolin recombinant immunoagent for cancer therapy.

Authors:  Dario Palmieri; Timothy Richmond; Claudia Piovan; Tyler Sheetz; Nicola Zanesi; Fulvia Troise; Cindy James; Dorothee Wernicke; Fata Nyei; Timothy J Gordon; Jessica Consiglio; Francesco Salvatore; Vincenzo Coppola; Flavia Pichiorri; Claudia De Lorenzo; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

3.  Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.

Authors:  Xinli Huang; Jianjie Qin; Sen Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.

Authors:  Lyndsay V Rhodes; Syreeta L Tilghman; Stephen M Boue; Shuchun Wang; Hafez Khalili; Shannon E Muir; Melyssa R Bratton; Qiang Zhang; Guangdi Wang; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Oncol Lett       Date:  2011-10-24       Impact factor: 2.967

Review 5.  miRNA - Therapeutic tool in breast cancer? Where are we now?

Authors:  Karolina Zaleska
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-26

6.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

Review 7.  Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer.

Authors:  Caroline Moyret-Lalle; Emmanuelle Ruiz; Alain Puisieux
Journal:  World J Clin Oncol       Date:  2014-08-10

8.  Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.

Authors:  Prasant Yadav; Masroor Mirza; Kajal Nandi; S K Jain; R C M Kaza; Nita Khurana; P C Ray; Alpana Saxena
Journal:  Tumour Biol       Date:  2016-09-30

9.  MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.

Authors:  Mithu Raychaudhuri; Holger Bronger; Theresa Buchner; Marion Kiechle; Wilko Weichert; Stefanie Avril
Journal:  Breast Cancer Res Treat       Date:  2017-02-08       Impact factor: 4.872

10.  Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs.

Authors:  Sayan Mullick Chowdhury; Tzu-Yin Wang; Sunitha Bachawal; Rammohan Devulapally; Jung Woo Choe; Lotfi Abou Elkacem; Butrus Khuri Yakub; David S Wang; Lu Tian; Ramasamy Paulmurugan; Jürgen K Willmann
Journal:  J Control Release       Date:  2016-08-05       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.